The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

The EU's health regulator is expected to decide in the first half of 2026 on the expanded use of Arexvy, GSK said, adding that it was working on making similar applications to U.S. and Japanese ...

EU approves first vaccine against common respiratory virus London (AFP) – The European Commission has followed the United States in approving the world's first vaccine for the Respiratory ...

Moderna's mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 ...